GRADE equity guidelines 3: considering health equity in GRADE guideline development: rating the certainty of synthesized evidence

Journal of Clinical Epidemiology

Volumn 90, Issue , 2017, Pages 76-83

  Welch, Vivian A ^a   Akl, Elie A ^b,c   Pottie, Kevin ^a,d   Ansari, Mohammed T ^a   Briel, Matthias ^e,f   Christensen, Robin ^g   Dans, Antonio ^h   Dans, Leonila ^h   Eslava Schmalbach, Javier ⁱ   Guyatt, Gordon ^f   Hultcrantz, Monica ^j,k   Jull, Janet ^d   Katikireddi, Srinivasa Vittal ^l   Lang, Eddy ^m   Matovinovic, Elizabeth ⁿ   Meerpohl, Joerg J ^o,p   Morton, Rachael L ^q   Mosdol, Annhild ^r   Murad, M Hassan ^s   Petkovic, Jennifer ^a   Schünemann, Holger ^c,f   Sharaf, Ravi ^t   Shea, Bev ^u   Singh, Jasvinder A ^v,w,x   Solà, Ivan ^y   Stanev, Roger ^z   Stein, Airton ^aa   Thabaneii, Lehana ^c   Tonia, Thomy ^ab   Tristan, Mario ^ac   Vitols, Sigurd ^ad   Watine, Joseph ^ae   Tugwell, Peter ^a   more..

^a UNIVERSITY OF OTTAWA   (Canada)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c MCMASTER UNIVERSITY   (Canada)

^d BRUYÈRE RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^g FREDERIKSBERG HOSPITAL   (Denmark)

^h UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

ⁱ HOSPITAL UNIVERSITARIO NACIONAL DE COLOMBIA   (Colombia)

^j Swedish Council on Technology Assessment in Health Care   (Sweden)

^k KAROLINSKA INSTITUTE   (Sweden)

^l UNIVERSITY OF GLASGOW   (United Kingdom)

^m UNIVERSITY OF CALGARY   (Canada)

ⁿ Faculty of Medicine Chiang Mai University   (Thailand)

^o UNIVERSITY OF FREIBURG   (Germany)

^p PARIS DESCARTES UNIVERSITY   (France)

^q UNIVERSITY OF SYDNEY   (Australia)

^r NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^s MAYO CLINIC   (United States)

^t DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^u OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^v BIRMINGHAM VA MEDICAL CENTER   (United States)

^w University of Alabama at Birmingham   (United States)

^x Mayo Clinic   (United States)

^y BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^z UNIVERSITY OF WASHINGTON   (United States)

^aa UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^ab UNIVERSITY OF BERN   (Switzerland)

^ac IHCAI Foundation Cochrane Central America Spanish speaking Caribbean   (Costa Rica)

^ad KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^ae Hôpital la Chartreuse   (France)

more..

Author keywords

Applicability; equity; GRADE; Guidelines; Health; Indirectness; Meta analysis; Subgroup analysis; Systematic review

Indexed keywords

ARTICLE; CONCEPTUAL FRAMEWORK; CONSENSUS; EFFECT SIZE; HEALTH EQUITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; EVIDENCE BASED PRACTICE; HUMAN; LITERATURE; META ANALYSIS (TOPIC); METHODOLOGY; STANDARDS; VULNERABLE POPULATION;

EVIDENCE-BASED PRACTICE; HEALTH EQUITY; HUMANS; META-ANALYSIS AS TOPIC; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN; REVIEW LITERATURE AS TOPIC; VULNERABLE POPULATIONS;

EID: 85023780664     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2017.01.015     Document Type: Article

References (43)

1. Whitehead, M., The concepts and principles of equity and health. Int J Health Serv 22 (1992), 429–445.
2. O'Neill, J., Tabish, H., Welch, V., Petticrew, M., Pottie, K., Clarke, M., et al. Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. J Clin Epidemiol 67 (2014), 56–64.
3. Welch, V., Akl, E.A., Guyatt, G., Pottie, K., Eslava-Schmalbache, J., Ansarif, M.T., et al. GRADE Equity: introduction: why health equity and GRADE guidelines?. J Clin Epidemiol, 2016.
4. National Institute for Health and Clinical Excellence. Positively equal: a guide to addressing equality issues in developing NICE clinical guidelines. 2nd ed., 2012, National Institute for Health and Clinical Excellence, London, UK Available at http://www.nice.org.uk. Accessed June 1, 2017.
5. Mitchell, J., Trangle, M., Degnan, B., Gabert, T., Haight, B., Kessler, D., et al. Depression, adult in primary care. 2013, Institute for Clinical Systems Improvement (ICSI) Available at https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_behavioral_health_guidelines/depression/. Accessed June 1, 2017.
6. Eslava-Schmalbach, J., et al. Colombia guidelines on complications of pregnancy and childbirth. 2013.
7. Suspected cancer in primary care: guidelines for investigation, referral and reducing ethnic disparities, 2009, New Zealand Guidelines Grup, Wellington, NZ Available at http://www.health.govt.nz/system/files/documents/publications/suspected-cancer-guideline-sep09.pdf. Accessed June 1, 2017.
8. Pottie, K., Greenaway, C., Feightner, J., Welch, V., Swinkels, H., Rashid, M., et al. Evidence-based clinical guidelines for immigrants and refugees. CMAJ 183 (2011), E824–E925.
9. Concannon, T.W., Meissner, P., Grunbaum, J.A., McElwee, N., Guise, J.M., Santa, J., et al. A new taxonomy for stakeholder engagement in patient-centered outcomes research. J Gen Intern Med 27 (2012), 985–991.
10. Maternal and child nutrition. NICE public health guidance 11. 2014, NICE, London, UK Available at https://www.nice.org.uk/guidance/ph11. Accessed June 1, 2017.
11. Harper, S., King, N.B., Young, M.E., Impact of selective evidence presentation on judgments of health inequality trends: an experimental study. PLoS One, 8, 2013, e63362.
12. Keppel, K., Pamuk, E., Lynch, J., Carter-Pokras, O., Kim, I., Mays, V., et al. Methodological issues in measuring health disparities. Vital Health Stat 2, 2005, 1–16.
13. Harper, S., Lynch, J., Methods for measuring cancer disparities: using data relevant to healthy people 2010 cancer-related objectives. Cancer surveillance monograph series, number 6. 2005, National Cancer Institute, Bethesda, MD Available at http://seer.cancer.gov/archive/publications/disparities/measuring_disparities.pdf. Accessed June 1, 2017.
14. Preventing dental caries: community water fluoridation. The community guide community preventive services task force, 2013 Atlanta.
15. Brown, T., Platt, S., Amos, A., Equity impact of population-level interventions and policies to reduce smoking in adults: a systematic review. Drug Alcohol Depend 138 (2014), 7–16.
16. Tugwell, P., Maxwell, L., Welch, V., Kristjansson, E., Petticrew, M., Wells, G., et al. Is health equity considered in systematic reviews of the Cochrane Musculoskeletal Group?. Arthritis Rheum 59 (2008), 1603–1610.
17. Humphreys, D.K., Ogilvie, D., Synthesising evidence for equity impacts of population-based physical activity interventions: a pilot study. Int J Behav Nutr Phys Act, 10, 2013, 76.
18. Schmid, C.H., Lau, J., McIntosh, M.W., Cappelleri, J.C., An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat Med 17 (1998), 1923–1942.
19. Burke, J.F., Sussman, J.B., Kent, D.M., Hayward, R.A., Three simple rules to ensure reasonably credible subgroup analyses. BMJ, 351, 2015, h5651.
20. Sun, X., Briel, M., Busse, J.W., You, J.J., Akl, E.A., Mejza, F., et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ, 344, 2012, e1553.
21. Sun, X., Briel, M., Busse, J.W., You, J.J., Akl, E.A., Mejza, F., et al. The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review. BMJ, 342, 2011, d1569.
22. Sun, X., Briel, M., Walter, S.D., Guyatt, G.H., Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ, 340, 2010, c117.
23. James, P.A., Oparil, S., Carter, B.L., Cushman, W.C., Dennison-Himmelfarb, C., Handler, J., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311 (2014), 507–520.
24. Leenen, F.H., Nwachuku, C.E., Black, H.R., Cushman, W.C., Davis, B.R., Simpson, L.M., et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 48 (2006), 374–384.
25. Manuel, D.G., Ho, T.H., Harper, S., Anderson, G.M., Lynch, J., Rosella, L.C., Modelling preventive effectiveness to estimate the equity tipping point: at what coverage can individual preventive interventions reduce socioeconomic disparities in diabetes risk?. Chronic Dis Inj Can 34 (2014), 94–102.
26. Spencer, F.A., Iorio, A., You, J., Murad, M.H., Schunemann, H.J., Vandvik, P.O., et al. Uncertainties in baseline risk estimates and confidence in treatment effects. BMJ, 345, 2012, e7401.
27. Iorio, A., Spencer, F.A., Falavigna, M., Alba, C., Lang, E., Burnand, B., et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ, 350, 2015, h870.
28. World Health Organization. Guideline: vitamin A supplementation in infants and children 6-59 months of age. 2011, World Health Organization, Geneva, Switzerland Available at http://apps.who.int/iris/bitstream/10665/44664/1/9789241501767_eng.pdf?ua=1&ua=1 Accessed June 1, 2017.
29. NACCHO/RACGP. National guide to a preventive health assessment for Aboriginal and Torres Strait Islander people. 2nd ed., 2012, National Aboriginal Community Controlled Health Organisation (NACCHO) and The Royal Australian College of General Practitioners (RACGP), South Melbourne Available at http://www.racgp.org.au/download/documents/AHU/2ndednationalguide.pdf. Accessed June 1, 2017.
30. Balshem, H., Helfand, M., Schunemann, H.J., Oxman, A.D., Kunz, R., Brozek, J., et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64 (2011), 401–406.
31. Lewin, S., Glenton, C., Munthe-Kaas, H., Carlsen, B., Colvin, C.J., Gulmezoglu, M., et al. Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med, 12, 2015, e1001895.
32. Guyatt, G.H., Oxman, A.D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., et al. GRADE guidelines: 8. Rating the quality of evidence–indirectness. J Clin Epidemiol 64 (2011), 1303–1310.
33. Bartlett, C., Doyal, L., Ebrahim, S., Davey, P., Bachmann, M., Egger, M., et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess 9 (2005), 1–152.
34. Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Golder, W., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359 (2002), 1187–1193.
35. O'Dell, J.R., Mikuls, T.R., Taylor, T.H., Ahluwalia, V., Brophy, M., Warren, S.R., et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 369 (2013), 307–318.
36. Charytan, D., Kuntz, R.E., The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 70 (2006), 2021–2030.
37. Barnett, K., Mercer, S.W., Norbury, M., Watt, G., Wyke, S., Guthrie, B., Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 380 (2012), 37–43.
38. Welch, V., Brand, K., Kristjansson, E., Smylie, J., Wells, G., Tugwell, P., Systematic reviews need to consider applicability to disadvantaged populations: inter-rater agreement for a health equity plausibility algorithm. BMC Med Res Methodol, 12, 2012, 187.
39. Greenaway, C., Sandoe, A., Vissandjee, B., Kitai, I., Gruner, D., Wobeser, W., et al. Tuberculosis: evidence review for newly arriving immigrants and refugees. CMAJ 183 (2011), E939–E951.
40. Smith, B.D., Morgan, R.L., Beckett, G.A., Falck-Ytter, Y., Holtzman, D., Teo, C.G., et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep 61 (2012), 1–32.
41. Furler, J., Magin, P., Pirotta, M., van Driel, M., Participant demographics reported in “Table 1” of randomised controlled trials: a case of “inverse evidence”?. Int J Equity Health, 11, 2012, 14.
42. Welch, V., Tugwell, P., Petticrew, M., de Montigny, J., Ueffing, E., Kristjansson, B., et al. How effects on health equity are assessed in systematic reviews of interventions. Cochrane Database Syst Rev(12), 2010, MR000028.
43. Morton, R.L., Schlackow, I., Mihaylova, B., Staplin, N.D., Gray, A., Cass, A., The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review. Nephrol Dial Transplant 31 (2016), 46–56.